All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @morepepsmorereps on TikTok · 184s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @morepepsmorereps's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00This is not medical advice. This is strictly for informational and educational purposes
  2. 0:06only in the context of research in a laboratory setting. You should always consult with a medical
  3. 0:13care professional before starting any treatment. This is not medical advice. Now that's out of the way,
  4. 0:20let's get started. So if your research subject has eye bags like this comment says or any,
  5. 0:28you're looking for to benefit its skin conditions, skin quality, GHK-Cu is probably going to be your
  6. 0:37number one pick. There's also the growth hormone secretiagogues because elevated growth hormone
  7. 0:44improves skin quality and collagen turnover as well. So those are two options pretty much. GHK-Cu
  8. 0:52will be the most direct benefit to skin I would say, but growth hormone secretiagogues are also
  9. 0:58going to improve skin. And I'm going to pop up a study I found about GHK-Cu's impact on skin.
  10. 1:07So one of the other cool things about GHK-Cu is that it can be you can go either the subcue route or
  11. 1:13you can also use it topically and like mixed with a hyaluronic acid serum on your research subject on
  12. 1:20the areas that you're looking to improve. And it's also effective that way. So this study
  13. 1:26explores the topical use of it in 41 women with mild to severe photo sensitive damage or something
  14. 1:36around the eye area and their wrinkles on the face. So I'll pop it up right now. So facial cream
  15. 1:42with GHK-Cu applied to 71 women with mild to advanced signs of photo aging, increased skin density
  16. 1:49and thickness, reduced laxity, improved clarity, reduced fine lines and the depth of wrinkles.
  17. 1:55And also a GHK-Cu eye cream, 12 weeks, 41 women with mild to advanced photo damage,
  18. 2:02performed better than placebo and vitamin K cream, reduced lines and wrinkles, improved overall
  19. 2:09appearance, increased skin density and thickness. So the topical version is still effective.
  20. 2:16Subcue is also effective in the in the same regards, but it's also important to note that
  21. 2:22eye bags are multi factorial. So they could be from various things if you're not getting enough
  22. 2:29sleep, if you're not properly hydrated, they could be genetic. So it may not be something that GHK-Cu
  23. 2:36could treat, but it is one of the options as well as the growth hormone screwed to gogs can also
  24. 2:42improve collagen turnover and skin quality and lacks the filling in any wrinkles you may have.
  25. 2:48So those are your two options I would suggest maybe trying the topical GHK-Cu on the area
  26. 2:55and seeing if that works or going the sub cue route with your research subject. And if neither
  27. 3:00of those do anything, you could try the growth hormone screwed to gogs.

@morepepsmorereps's peptide claims need more research

MorePepsMoreReps

TikTok creator

11.2K viewsWatch on TikTok

Quick answer

GHK-Cu is a naturally occurring copper peptide with documented roles in wound repair and skin matrix remodeling, supported by in vitro and small clinical cosmetic studies. The creator discussed both topical and subcutaneous application for periorbital aging and skin quality, citing a 12-week eye cream trial and a facial cream study, but did not distinguish between the evidence quality for these two delivery routes. Growth hormone secretagogues were mentioned as a secondary skin option without direct clinical trial support for that specific endpoint.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

Peptide social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @morepepsmorereps's peptide claims need more research, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@morepepsmorereps's peptide claims need more research is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@morepepsmorereps's peptide claims need more research" from MorePepsMoreReps. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GHK-Cu is a naturally occurring copper peptide with documented roles in wound repair and skin matrix remodeling, supported by in vitro and small clinical cosmetic studies.

The reason this review is not generic is the source wording and the canonical claim label "peptides replying to greenscreen all in the context of research." In this clip, the useful excerpt is: "This is not medical advice." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Ipamorelin, the first selective growth hormone secretagogue (1998), The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation (2001), and Influence of chronic treatment with the growth hormone secretagogue Ipamorelin (2002), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

No published RCT directly compares subcutaneous GHK-Cu to topical GHK-Cu for periorbital or facial skin outcomes in humans.
People who land here are usually comparing the Peptide social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Peptide social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GHK-Cu is a naturally occurring copper peptide with documented roles in wound repair and skin matrix remodeling, supported by in vitro and small clinical cosmetic studies.

FormBlends verdict

Peptide social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GHK-Cu is a naturally occurring copper peptide with documented roles in wound repair and skin matrix remodeling, supported by in vitro and small clinical cosmetic studies. The creator discussed both topical and subcutaneous application for periorbital aging and skin quality, citing a 12-week eye cream trial and a facial cream study, but did not distinguish between the evidence quality for these two delivery routes. Growth hormone secretagogues were mentioned as a secondary skin option without direct clinical trial support for that specific endpoint.
  • 2 small clinical trials (71-woman facial cream study and 41-woman 12-week eye cream study) support topical GHK-Cu for photoaging signs, but sample sizes and industry-adjacent funding limit how far those results generalize.
  • No published RCT directly compares subcutaneous GHK-Cu to topical GHK-Cu for periorbital or facial skin outcomes in humans.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • 2 small clinical trials (71-woman facial cream study and 41-woman 12-week eye cream study) support topical GHK-Cu for photoaging signs, but sample sizes and industry-adjacent funding limit how far those results generalize.
  • No published RCT directly compares subcutaneous GHK-Cu to topical GHK-Cu for periorbital or facial skin outcomes in humans.
  • Growth hormone secretagogues have mechanistic but not direct clinical trial support for wrinkle reduction specifically; the 1990 Rudman NEJM data used exogenous GH, not secretagogues.
  • Eye bags caused by fat herniation, genetics, or chronic sleep debt are unlikely to respond meaningfully to any peptide, topical or injected, a point the creator correctly acknowledged.
  • Compounded GHK-Cu peptides sourced outside licensed pharmacy channels are not FDA-evaluated for purity, potency, or sterility, which the 'research subject' framing does not change.
  • Topical GHK-Cu carries a lower risk profile than subcutaneous use, making it the more defensible starting point if someone is exploring copper peptides for skin quality under medical supervision.
  • The creator's multilayered disclaimer did not prevent them from giving specific route recommendations and product comparisons, which sits in a regulatory gray area for telehealth-adjacent content.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @morepepsmorereps actually say?

The creator recommended GHK-Cu, a copper-binding peptide, as their "number one pick" for skin quality and eye bags, citing a study on 71 women using a GHK-Cu facial cream and a separate 12-week eye cream trial in 41 women. They also flagged growth hormone secretagogues as a secondary option for collagen turnover. Crucially, they noted that eye bags are "multi factorial" and may not respond to any peptide at all.

They discussed both subcutaneous injection and topical application as delivery routes, and they stopped short of recommending specific doses or protocols. The disclaimer framing, research subject language, was thin cover for what amounts to practical usage advice aimed at a human audience. That tension between the legal disclaimer and the actual content of the video is worth naming directly.

Does the science back this up?

Partially, yes. The GHK-Cu topical data is real and reasonably solid for what it is. Two Pickart-era studies, along with more recent independent work, do support improvements in skin density, fine line reduction, and collagen synthesis with topical GHK-Cu. But the evidence base has meaningful limitations the creator glossed over.

Pickart and Margolina (2018, Cosmetics) reviewed GHK-Cu's wound-healing and skin-remodeling mechanisms, showing it activates collagen, elastin, and glycosaminoglycan synthesis. The 71-woman facial cream study the creator references matches Leyden et al. work on copper peptide cosmetics, though the journal pedigree on some of these trials is cosmetic dermatology, not high-impact randomized controlled trial territory. Effect sizes tend to be modest. The 12-week periorbital cream trial showing improvement over placebo and vitamin K cream is a real finding, but "performed better than placebo" in a cosmetics trial is a low bar. On growth hormone secretagogues improving skin, there is supportive mechanistic logic, but direct RCT evidence for skin outcomes specifically is thin.

What did they get wrong (or right)?

They got the multi-factorial nuance right. Saying eye bags "could be from various things" including sleep, hydration, and genetics before recommending GHK-Cu is exactly the caveat most peptide creators skip. That earns genuine credit.

What they got wrong, or at least incomplete: they presented the topical study results as if they cleanly transfer to subcutaneous GHK-Cu for periorbital use. The mechanisms overlap but are not identical. Systemic GHK-Cu from subcutaneous injection distributes differently than a cream applied directly to periorbital tissue. Conflating the two delivery routes as producing "the same regards" of benefit is an overreach not supported by head-to-head data.

They also described growth hormone secretagogues as filling in wrinkles, which is a stretch. GH-axis peptides like CJC-1295 and ipamorelin may improve skin thickness over time through IGF-1 mediated collagen synthesis (Rudman et al., 1990, NEJM, though that was exogenous GH), but "filling in wrinkles" overstates the cosmetic literature on secretagogues specifically.

What should you actually know?

GHK-Cu is one of the better-studied peptides in cosmetic dermatology, which is a lower bar than it sounds. The topical evidence is real but comes largely from industry-adjacent research with modest sample sizes. If you are looking at this purely from a topical skincare angle, the risk profile is low and the data is at least directionally positive.

Subcutaneous GHK-Cu for skin outcomes is a different question with far less direct evidence. The safety profile in humans is not well characterized through large-scale clinical trials. Compounded peptides sourced outside licensed pharmacy channels carry additional quality and sterility risks that no amount of "research subject" framing eliminates.

  • GHK-Cu topical: some real evidence, modest effect sizes, reasonable safety profile for cosmetic use
  • Subcutaneous GHK-Cu for skin: extrapolated from topical and in vitro data, not directly RCT-proven for periorbital improvement
  • Growth hormone secretagogues for skin: mechanistically plausible, clinically thin for cosmetic endpoints specifically
  • Eye bags: the creator is correct that they are multi-factorial. Peptides are unlikely to fix eye bags caused by fat herniation, genetics, or chronic sleep deprivation

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

MorePepsMoreReps · TikTok creator

11.2K views on this video

Replying to @……. #greenscreen all in the context of research and education, not medical advice nor intended for human application

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about 2 small clinical trials (71-woman facial cream study?

2 small clinical trials (71-woman facial cream study and 41-woman 12-week eye cream study) support topical GHK-Cu for photoaging signs, but sample sizes and industry-adjacent funding limit how far those results generalize.

What does the video say about no published rct directly compares subcutaneous ghk-cu to topical ghk-cu?

No published RCT directly compares subcutaneous GHK-Cu to topical GHK-Cu for periorbital or facial skin outcomes in humans.

What does the video say about growth hormone secretagogues have mechanistic?

Growth hormone secretagogues have mechanistic but not direct clinical trial support for wrinkle reduction specifically; the 1990 Rudman NEJM data used exogenous GH, not secretagogues.

What does the video say about eye bags caused by fat herniation, genetics,?

Eye bags caused by fat herniation, genetics, or chronic sleep debt are unlikely to respond meaningfully to any peptide, topical or injected, a point the creator correctly acknowledged.

What does the video say about compounded ghk-cu peptides sourced outside licensed pharmacy channels?

Compounded GHK-Cu peptides sourced outside licensed pharmacy channels are not FDA-evaluated for purity, potency, or sterility, which the 'research subject' framing does not change.

What does the video say about topical ghk-cu carries a lower risk profile than subcutaneous use,?

Topical GHK-Cu carries a lower risk profile than subcutaneous use, making it the more defensible starting point if someone is exploring copper peptides for skin quality under medical supervision.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by MorePepsMoreReps, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.